To validate these data, we used second generation class I and II HDAC inhibitor, AR4231,32, currently in clinical trial for acoustic schwannoma and meningioma (phase 0), as well as leukemia (phase I)33, which has high blood–brain barrier permeability. Here, HDAC9 is linked to leukemia.